First experiences with treatment of chronic hepatitis C with Pegintron and Rebetol in the Czech Republic
Authors:
Jan Šperl Za Kolektiv Autorů
Authors‘ workplace:
Institut klinické a experimentální medicíny v Praze
Klinika hepatogastroenterologie
Přednosta Doc. MUDr. Julius Špičák, CSc.
Published in:
Vnitř Lék 2005; 51(11): 1314-1318
Category:
Non-reviewed articles
Overview
Based on retrospectively collected data, the team evaluated results for treatment of the first hundred of patients treated for chronic hepatitis C with PegIntron and Rebetol in the Czech Republic between 2003 and 2005. The treatment resulted in sustained virological response (SVR) in 53 out of 100 patients (53.0%). The effect of treatment was highest for patients without previous treatment, with SVR ratio 34 versus 53 (62.2%). The effect of treatment was lower in patients who relapsed after previous treatment with conventional interferon-α or showed no response to treatment at all, with SVR ratio 14 versus 27 (51.9%), and 5 versus 20 (25.0%), respectively. The effect of treatment in patients with genotype 1 was comparable with that in patients for whom genotype was not available, with SVR ratio 35 versus 65 (58%), and 14 versus 25 (56%), respectively, but we assume genotype 1 prevalence in the latter group, too. The effect of PegIntron and Rebetol in treatment of chronic hepatitis C in Czech patients coincides with results reported in published clinical studies.
Keywords:
chronic hepatitis C – PegIntron – Rebetol – virological response
Sources
1.Manns MP, McHutchison JG, Gordon SC et al. Peginterferon alfa–2b plus ribavirin compared with interferon alfa–2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 22 (358): 958–965.
2.Davis GL, Wong JB, McHutchison JG et al. Early virological response to treatment with peginterferon alfa–2b plus ribavirin in patients with chronic hepatitis C. Hepatology 2003; 38: 645–652.
3.Shiffman ML, Di Bisceglie AM, Lindsay KL et al. Peginterferon alfa–2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment. Gastroenterology 2004; 126: 1015–1023.
4.Urbánek P, Husa P, Šperl J et al.: Diagnostika a léčba chronické hepatitidy C. Doporučený postup české hepatologické společnosti a společnosti infekčního lékařství čLS JEP. Klinická mikrobiologie a infekční lékařství 2005; 11: 149–196.
5.McHutchison JG, Manns M, Patel K et al. International Hepatitis Interventional Therapy Group. Adherence to combination therapy enhances sustained response in genotype–1–infected patients with chronic hepatitis C. Gastroenterology 2002; 123: 1061–1069.
6.Lindsay KL, Trepo C, Heintges T, Shiffman ML et al. Hepatitis Interventional Therapy Group. A randomized, double–blind trial comparing pegylated interferon alfa–2b to interferon alfa–2b as initial treatment for chronic hepatitis C. Hepatology 2001; 34: 395–403.
7.Zeuzem S, Hultcrantz R, Bourliere M et al. Peginterferon alfa–2b plus ribavirin for treatment of chronic hepatitis C in previously untreated patients infected with HCV genotypes 2 or 3. J Hepatol 2004; 40: 993–9. Erratum in: J Hepatol. 2005, 42: 434.
Labels
Diabetology Endocrinology Internal medicineArticle was published in
Internal Medicine
2005 Issue 11
Most read in this issue
- Regression equations for QT and QTc intervals of the electrocardiogram
- A rare complication after aortocoronary bypass: acute cholestatic hepatitis and agranulocytosis induced by ticlopidin and simvastatin in patients allergic to salicilates
- Type 1A diabetes mellitus and autoimmunity
- New possibilities in the treatment of chronic thromboembolic pulmonary hypertension